VJOncology is committed to improving our service to you

ESMO 2017 | How were biosimilars discussed at ESMO 2017?

VJOncology is committed to improving our service to you

Richard Markus

Richard Markus, MD, PhD, from Amgen, Los Angeles, CA, talks to us about a symposium at the European Society for Medical Oncology (ESMO) 2017 conference in Madrid, Spain which focused on biosimilars in cancer treatment. Dr Markus discusses APB 980, a biosimilar of the agent trastuzumab developed by Amgen, and talks us through some of the other topics presented during the symposium.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter